CSIMarket
 


Charles River Laboratories International inc   (CRL)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 

CRL's Net Income Growth by Quarter and Year

Charles River Laboratories International Inc 's Net Income results by quarter and year




CRL Net Income (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 188.95 189.11 139.83 144.19
III Quarter September 88.02 97.61 105.16 102.61
II Quarter June 99.44 110.66 89.92 67.67
I Quarter March 103.95 95.23 63.94 50.84
FY   480.36 492.61 398.85 365.31



CRL Net Income fourth quarter 2023 Y/Y Growth Comment
Charles River Laboratories International Inc reported decrease in Net Income in the fourth quarter 2023 by -0.08% to $ 188.95 millions, from the same quarter in 2022.
The decrease in the fourth quarter 2023 Charles River Laboratories International Inc 's Net Income compares unfavorably to the Company's average Net Income rise of 22.86%.

Looking into fourth quarter 2023 results within Medical Laboratories industry 2 other companies have achieved higher Net Income growth. While Charles River Laboratories International Inc ' s Net Income decline of -0.08% ranks overall at the positon no. 234 in the fourth quarter 2023.




CRL Net Income ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December -0.08 % 35.24 % -3.02 % 79.1 %
III Quarter September -9.82 % -7.18 % 2.49 % 39.51 %
II Quarter June -10.14 % 23.06 % 32.88 % 52.72 %
I Quarter March 9.16 % 48.94 % 25.77 % -8.71 %
FY   -2.49 % 23.51 % 9.18 % 43.79 %

Financial Statements
Charles River Laboratories International Inc 's fourth quarter 2023 Net Income $ 188.95 millions CRL's Income Statement
Charles River Laboratories International Inc 's fourth quarter 2022 Net Income $ 189.11 millions Quarterly CRL's Income Statement
New: More CRL's historic Net Income Growth >>


CRL Net Income (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December 114.67 % 93.74 % 32.97 % 40.52 %
III Quarter September -11.48 % -11.79 % 16.95 % 51.63 %
II Quarter June -4.34 % 16.2 % 40.63 % 33.1 %
I Quarter March -45.03 % -31.9 % -55.66 % -36.85 %
FY (Year on Year)   -2.49 % 23.51 % 9.18 % 43.79 %




Net Income fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #3
Healthcare Sector #21
Overall #234

Net Income Y/Y Growth Statistics
High Average Low
149.27 % 22.86 % -14.82 %
(March 31, 2016)   (Sep 29 2018)
Net Income fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #3
Healthcare Sector #21
Overall #234
Net Income Y/Y Growth Statistics
High Average Low
149.27 % 22.86 % -14.82 %
(March 31, 2016)   (Sep 29 2018)

Net Income by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Charles River Laboratories International Inc 's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
114.67 % 9.75 % -55.66 %
(Dec 30 2023)  


CRL's IV. Quarter Q/Q Net Income Comment
Charles River Laboratories International inc achieved in the IV. Quarter 2023 above company average sequential Net Income doubling of 114.67%, to $ 188.95 millions, from $88.02 millions in the third quarter.
Medical Laboratories company is impressively improving, with recording above normal increase, but also improving rate.

Within Medical Laboratories industry Charles River Laboratories International inc achieved highest sequential Net Income growth. While Charles River Laboratories International Inc 's Net Income growth quarter on quarter, overall rank is 68.


Net Income Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #0
Healthcare Sector #8
Overall #68
Net Income Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #0
Healthcare Sector #8
Overall #68
Net Income Q/Q Growth Statistics
High Average Low
114.67 % 9.75 % -55.66 %
(Dec 30 2023)  


CRL's IV. Quarter Q/Q Net Income Comment
Charles River Laboratories International inc achieved in the IV. Quarter 2023 above company average sequential Net Income doubling of 114.67%, to $ 188.95 millions, from $88.02 millions in the third quarter.
Charles River Laboratories International Inc is impressively improving, with claiming better then regular increase, and additionally accelerating rate.

Within Medical Laboratories industry Charles River Laboratories International inc achieved highest sequential Net Income growth. While Charles River Laboratories International Inc 's Net Income growth quarter on quarter, overall rank is 68.


Charles River Laboratories International Inc 's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Dec 30 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jul 01 2023)
12 Months Ending
(Apr 01 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Net Income 12 Months Ending $ 480.37 $ 480.52 $ 490.12 $ 501.34 $ 492.61
Y / Y Net Income Growth (TTM) -2.48 % 8.39 % 8.7 % 16.56 % 23.51 %
Year on Year Net Income Growth Overall Ranking # 170 # 808 # 797 # 699 # 730
Seqeuential Net Income Change (TTM) -0.03 % -1.96 % -2.24 % 1.77 % 11.12 %
Seq. Net Income Growth (TTM) Overall Ranking # 592 # 1044 # 941 # 792 # 904




Cumulative Net Income growth Comment
For the 12 months ended Dec 30 2023 Charles River Laboratories International Inc reported a decrease in Net Income by -2.48% year on year, to $480 millions, compare to the 8.39% growth at Sep 30 2023.

Among companies within the Healthcare sector 16 other companies have achieved higher trailing twelve month Net Income growth. While Total ranking has impoved so far to 170, from total ranking in previous quarter at 808.

Net Income TTM Q/Q Growth Statistics
High Average Low
149.27 %
22.86 %
-14.82 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 4
Healthcare Sector # 17
Overall # 170

Net Income TTM Y/Y Growth Statistics
High Average Low
149.27 %
22.86 %
-14.82 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 4
Sector # 51
S&P 500 # 592
Cumulative Net Income growth Comment
For the 12 months ended Dec 30 2023 Charles River Laboratories International Inc reported a decrease in Net Income by -2.48% year on year, to $480 millions, compare to the 8.39% growth at Sep 30 2023.

Among companies within the Healthcare sector 16 other companies have achieved higher trailing twelve month Net Income growth. While Total ranking has impoved so far to 170, from total ranking in previous quarter at 808.

Net Income TTM Q/Q Growth Statistics
High Average Low
149.27 %
22.86 %
-14.82 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 4
Healthcare Sector # 17
Overall # 170

Net Income TTM Y/Y Growth Statistics
High Average Low
149.27 %
22.86 %
-14.82 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 4
Sector # 51
S&P 500 # 592




Other Net Income Growth
Medical Laboratories Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
CRL's Net Income Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for CRL's Competitors
Net Income Growth for Charles River Laboratories International Inc 's Suppliers
Net Income Growth for CRL's Customers

You may also want to know
CRL's Annual Growth Rates CRL's Profitability Ratios CRL's Asset Turnover Ratio CRL's Dividend Growth
CRL's Roe CRL's Valuation Ratios CRL's Financial Strength Ratios CRL's Dividend Payout Ratio
CRL's Roa CRL's Inventory Turnover Ratio CRL's Growth Rates CRL's Dividend Comparisons



Companies with similar Net Income decrease for the quarter ending Dec 30 2023 within Healthcare SectorY/Y Change %Net Income for the quarter ending Dec 30 2023
Charles River Laboratories International inc -0.08%$ -0.081 millions
Sanuwave Health Inc -0.23%$ -0.232 millions
Regeneron Pharmaceuticals Inc -3.13%$ -3.133 millions
Haemonetics Corporation-5.17%$ -5.169 millions
Resmed Inc -7.16%$ -7.165 millions
Edwards Lifesciences Corporation-7.20%$ -7.204 millions
Star Equity Holdings Inc -9.48%$ -9.481 millions
Bristol myers Squibb Company-12.99%$ -12.988 millions
Gilead Sciences Inc -13.23%$ -13.227 millions
Utah Medical Products Inc-13.50%$ -13.499 millions
Alpha Tau Medical Ltd -13.64%$ -13.640 millions
Masimo Corp-17.13%$ -17.125 millions
Merit Medical Systems Inc-17.28%$ -17.281 millions
Fresenius Medical Care Ag-18.10%$ -18.099 millions
Qiagen N v -19.35%$ -19.354 millions
Mettler toledo International Inc -30.49%$ -30.485 millions
Avantor Inc -30.49%$ -30.487 millions
Sanofi-35.93%$ -35.926 millions
Icu Medical Inc-38.15%$ -38.151 millions
Amedisys Inc -39.71%$ -39.707 millions
Avanos Medical Inc -40.34%$ -40.341 millions
Embecta Corp -42.90%$ -42.898 millions
Pro dex Inc -43.12%$ -43.117 millions
Becton Dickinson And Company-44.79%$ -44.794 millions
Bio techne Corp-45.08%$ -45.075 millions
Harmony Biosciences Holdings inc -45.15%$ -45.150 millions
Exagen Inc -45.72%$ -45.721 millions
Amgen Inc -52.54%$ -52.537 millions
Biogen Inc -54.70%$ -54.704 millions
Taro Pharmaceutical Industries Ltd-56.33%$ -56.330 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com